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Objectives
At the conclusion of this session, the participant will be 
able to:
 State the evidence related to effectiveness and potential risks 
associated with nonopioid treatments for chronic pain.
 Outline nonpharmacologic and nonopioid pharmacologic 
treatment options for various chronic pain conditions.
 Review patient evaluation methods that can be used to identify 
the most appropriate treatment options for chronic pain.
 Describe the role of patient beliefs and expectations, and value 
of exercise, education, and nonopioid drug treatments in the 
management of musculoskeletal pain complaints.
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Effectiveness and harms of nonopioid treatments 
for chronic pain
• Table 3: Effectiveness and Harms of 
Nonpharmacologic Treatments 
• From: CDC Guideline for Prescribing 
Opioids for Chronic Pain—United 
States, 2016. JAMA. 2016;315(15):1624-
1645.
• The JAMA Network
From: CDC Guideline for Prescribing Opioids for Chronic 
Pain—United States, 2016. JAMA. 2016;315(15):1624-1645.
Overview of findings from the evidence reviews
• Insufficient evidence to determine whether pain relief, 
function, or quality of life improves with long-term opioid 
therapy (most RCTs <6 weeks)
• Long-term opioid use for chronic pain is associated with 
serious risks, including abuse, dependence and overdose
• Many non-opioid therapies can improve chronic pain with 
less risk for harm
• When opioids are used, they are more likely to be effective if 
combined with other approaches
Opioids not first-line or routine
therapy for chronic pain
• Nonpharmacologic therapy and nonopioid pharmacologic 
therapy are preferred for chronic pain. 
• Clinicians should consider opioid therapy only if expected 
benefits for both pain and function are anticipated to 
outweigh risks to the patient. 
• If opioids are used, they should be combined with 
nonpharmacologic therapy and nonopioid pharmacologic 
therapy, as appropriate. 
(Recommendation category A: Evidence type: 3)
Effective treatments for chronic pain
• Nonpharmacologic therapies 
– Exercise therapy
– Cognitive-behavioral therapy
• Nonopioid pharmacologic treatments
– Acetaminophen
– NSAIDs, and COX-2 inhibitors 
– Selected anticonvulsants (e.g., pregabalin, gabapentin)
– Selected antidepressants (tricyclics, SNRIs)
• Interventional approaches
• Multimodal and multidisciplinary therapies 
Nonpharmacologic therapies can
• Result in sustained improvements in pain and 
function without apparent risks
• Encourage active patient participation in the 
care plan
• Address the effects of pain in the patient’s life
Exercise therapy
• High-quality evidence for reduced pain and improved 
function for hip or knee osteoarthritis 
– Immediately after treatment 
– Improvements sustained for at least 2–6 months
• Previous guidelines strongly recommended aerobic, aquatic, 
and/or resistance exercises for patients with hip or knee 
osteoarthritis 
• Can reduce pain and improve function in low back pain 
• Can improve global well-being, fibromyalgia symptoms, and 
physical function in fibromyalgia 
Cognitive behavioral therapy (CBT)
• Addresses psychosocial contributors to pain 
and improves function 
• Trains patients in behavioral techniques 
• Helps patients modify situational factors and 
cognitive processes that exacerbate pain 
• Has small positive effects on disability and 
catastrophic thinking
Access to nonpharmacologic treatments
• Access and cost can be barriers 
• Aspects of these approaches can be used even when there is 
limited access to specialty care 
– RCT: no difference in reduced chronic low back pain 
intensity, frequency or disability between 
• Patients assigned to relatively low-cost group aerobics 
• Individual physiotherapy sessions 
– Low-cost options to integrate exercise:
• Brisk walking in public spaces 
• Use of public recreation facilities for group exercise 
Using CBT principles in primary care
• Encourage patients to take an active role 
• Teach relaxation techniques 
• Support engaging in beneficial but potentially anxiety-
provoking activities, such as exercise
• Support patient coping strategies 
• Refer patients to support, self-help, and educational 
community-based programs 
• Refer patients with more entrenched anxiety or fear related 
to pain, or other significant psychological distress, for formal 
therapy with a mental health specialist
Acetaminophen
• Multiple guidelines: acetaminophen first-line for 
– Osteoarthritis 
– Low back pain 
• Can be hepatotoxic at > 3-4 grams/day and at lower dosages 
in patients with chronic alcohol use or liver disease
– Avoid in liver failure 
– Reduce dosage in patients with 
• Hepatic insufficiency 
• History of alcohol abuse 
NSAIDs and cyclooxygenase 2 (COX-2) inhibitors 
• NSAIDs first-line treatment for 
– Osteoarthritis 
– Low back pain 
• NSAIDs and COX-2 inhibitor risks:
– Gastritis, gastrointestinal bleeding or perforation 
– Fluid retention, renal and cardiovascular risks 
– Interference with platelet aggregation
– Topical NSAIDs have less systemic risk than oral NSAIDs
Selected antidepressants 
• Tricyclics (TCAs, e.g., amitriptyline) and SNRIs (e.g., duloxetine) 
are effective and recommended in multiple guidelines for 
– Neuropathic pain (e.g., diabetic neuropathy, post-herpetic 
neuralgia)
– Fibromyalgia symptoms
• TCAs relatively contraindicated in severe cardiac disease, 
particularly conduction disturbances
• Start TCAs at low dosages, titrate up as needed and tolerated
– Often effective at lower dosages than for depression
– Anticholinergic effects include sedation--use at bedtime
Selected anticonvulsants
• Selected anticonvulsants (e.g., pregabalin, gabapentin) are 
effective and recommended in multiple guidelines for 
– Neuropathic pain (e.g., diabetic neuropathy, post-herpetic 
neuralgia)
– Fibromyalgia symptoms
• Start pregabalin or gabapentin at low dose and increase 
gradually given dose-dependent dizziness and sedation 
• Check baseline and periodic CBC and LFTs with 
carbamazepine
Interventional approaches
• Injections can improve short-term pain and function
– Arthrocentesis and intraarticular glucocorticoid injection 
in rheumatoid arthritis or osteoarthritis 
– Subacromial corticosteroid injection in rotator cuff disease
– Epidural injection for lumbar radiculopathy
• Potential risks
– Articular cartilage changes (in osteoarthritis) 
– Sepsis
– Rare but serious adverse events associated with epidural 
injection:  loss of vision, stroke, paralysis, death
Multimodal and multidisciplinary therapies
• Can reduce long-term pain and disability more effectively 
than single modalities 
• Involve coordination of medical, psychological, and social 
aspects of care 
• Are not always available or reimbursed by insurance 
• Can be time-consuming and costly for patients
• Should be considered for patients not responding to single-
modality therapy, or who have severe functional deficits
• Combinations should be tailored depending on patient 
needs, cost, and convenience
Selection of therapy: evaluation
• Evaluate patients, establish or confirm diagnosis 
– Focused history, including 
• History and characteristics of pain 
• Contributing factors (psychosocial stressors, sleep) 
– Physical exam 
– Imaging only if indicated, e.g., if
• Severe or progressive neurologic deficits are present or 
• Serious underlying conditions are suspected 
• For complex pain syndromes, consider pain specialty 
consultation to assist with diagnosis as well as management
Selection of therapy: role of pain mechanism 
and diagnosis
• NSAIDs for nociceptive pain (e.g., osteoarthritis, muscular back 
pain) 
• Selected antidepressants or anticonvulsants for neuropathic 
pain (e.g., diabetic neuropathy, postherpetic neuralgia) or 
fibromyalgia); topical lidocaine for localized neuropathic pain
• Physical or occupational therapy can address posture, 
weakness, or repetitive motions contributing to 
musculoskeletal pain
• Surgical intervention can relieve mechanical/compressive pain 
• Glucose control can prevent progression of diabetic 
neuropathy
• Immune-modulating agents useful in rheumatoid arthritis 
Selection of therapy: role of risk factors for harm
• Use medications only after determining expected benefits 
outweigh risks given patient-specific factors 
• Consider falls risk when selecting and dosing potentially 
sedating medications (e.g., tricyclics, anticonvulsants, opioids) 
• Weigh risks and benefits of use, dose, and duration of NSAIDs 
when treating older adults, patients with hypertension, renal 
insufficiency, or heart failure, or those at risk for peptic ulcer 
disease or cardiovascular disease
• Consider topical NSAIDs over oral NSAIDs for localized 
osteoarthritis (e.g., knee osteoarthritis) in patients aged ≥ 75
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• Follow @DebHouryCDC and @CDCInjury for 
useful information and important Guideline 
updates.
Find out more about Injury Center social 
media: 
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CDC Gu ide l i ne fo r  P rescr ib ing  Op io ids  
fo r  Ch ron i c  Pa in
NON-OPIOID MEDICATIONS & 
NONPHARMACOLOGIC TREATMENT
1. Outline the differential diagnoses for this patient’s 
symptoms, and the methods to choose among them.
2. Identify patient belief systems that might interfere 
with treatment, and strategies to address these.
3. Review the role of patient education in setting 
expectations when managing musculoskeletal pain.
4. Describe the rationale for exercise therapy, and how 
to overcome patient barriers to physical therapy.
5. Defend the rationale for use of a tricyclic 




• Age: 38 
• Symptoms
o Non-radicular, aching, stabbing neck pain x 3 weeks
o Intermittent neck pain/headaches starting in 2008.  Also: 
headaches, diffuse bilateral upper extremity pain + thoracic 
& lumbar spine 
• Electromyography (EMG) 6 years ago: normal
• Magnetic resonance image (MRI) 3 weeks ago: 
o Degenerative disc disease (DDD) + foraminal narrowing 
C5-6; C6-7
PATIENT HISTORY – 7/8/14
• Rx: oxycodone 5/325 twice daily; 
cyclobenzaprine 10 mg at bedtime
• Mood: “grumpy because of pain”
• Past medical history: Irritable Bowel 
Syndrome  
• Smokes ½ packs per day; no illicit drugs
• Lives with girlfriend + 10 y/o daughter
• Job: builds cranes; can’t make it to work one 
day per week 
• Activity: 3 hours in recliner after work
HISTORY CONTINUED
• Pain, interference with Enjoyment, General function (PEG) tool
± Brief Pain Inventory (BPI)
± Promise 10
± Oswestry Disability Index (ODI)
± Roland Morris Disability Questionnaire (RMDQ)
• Personal Health Questionnaire PHQ-9 + General Anxiety Disorder 
GAD-7 
o Or short version PHQ-4
o When elevated ↑ : full PHQ-9, GAD-7 plus Primary Care-Post Traumatic 
Stress Disorder PC-PTSD
• Alcohol Use Disorders Identification Test AUDIT-C 
• ORT, SOAPP, COMM, or DIRE
o All of these misuse/addiction tools are widely used, though poor predictive 
validity
• Prescription Drug Monitoring Program (PDMP)
o Important to check, he may request an opioid refill!




• Combines Generalized Anxiety 
Disorder GAD-7 + PHQ-9
• Score ≥ 6 needs attention 
Krebs 2009, Kroenke 2009
Pain average, interference with 
Enjoyment of life, and interference 
with General activity 
(PEG) Assessment Scale 
• Pain average, interference with Enjoyment of life, and 
interference with General activity 
• (PEG) Assessment Scale 
• Patient Health Questionnaire PHQ-4
– Combines Generalized Anxiety Disorder 
GAD-7 + PHQ-9
– Score ≥ 6 needs attention
Krebs 2009, Kroenke 2009
• Pain intensity: 6/10
• Pain interference with:
o General function: 7/10




• Mood: PHQ-4: 6/12
o …so added, GAD-7: 6/21 
o …and, PHQ-9: 8/27
PATIENT REPORTED OUTCOMES (PROs)
Patient self-selected important 
activity (“work”): 8
Oswestry Disability Index: 50
Opioid Risk Tool:  4
Satisfaction with pain treatment:  
2/10
• Height: 5’7” and Weight:119 lbs
o Normal = 130 lbs; Body mass index (BMI) 18.6
• Vital Signs normal
• 14/18 “tender points”
• Limited range of motion – neck, lumbar
• Neuro –
o Normal deep tendon reflexes (DTRs) 
o No long tract signs




1. Axial neck pain (“cervicalgia”)
2. Fibromyalgia vs. inflammatory arthritis
3. Weight loss, unexplained
4. Long-term opioid therapy, low dose
5. Irritable bowel syndrome
6. Mild depression and anxiety




Widespread Pain Index (0-19 
points during the past 7 days)
Symptom Severity (0-12 
points during the past 7 days)
Clauw 2014, Wolfe 2009 
WIDESPREAD PAIN & CO-OCCURRING PAIN DISORDERS
Symptom Intensity Scale
Clauw 2014, Wolfe 2009 
“Fibromyalgia-ness”
Plan
1. Discuss likely diagnoses and treatment plan
2. Set up appropriate expectations
• Records from current health care provider(s)
• Intentions and plans regarding long-term opioids 
3. Labs
• C-reactive protein (CRP)
• Anti-cyclic citrullinated peptide antibody (anti-CCP)
• Anti-nuclear antibody (ANA) 
4. Visit summary with links to info on Fibromyalgia
(e.g. fibroguide.com)
ESTABLISH TREATMENT PLAN
• Resists diagnosis of Fibromyalgia 
…“it is a ‘psychological’ condition”
• Continue discussion of Fibromyalgia 
pathophysiology
o Offer brief education re pain mechanisms and 
treatment to help understand pain
o Suggest educational materials
• Referral to physical therapy (PT) for neck 
range of motion (ROM)/strength + general 
conditioning
FOLLOW UP – 7/22/14
1. Exercise is good; PT is a means
“Closest thing to a wonder drug? Try exercise”
2. Optimal exercise?  No definite evidence
3. PT/exercise often “fails”  
“…made my pain worse!”
4. Clinician interventions
• Find PT who will work with complex pts
• Ask about progress – have pt demonstrate
• Basic concepts – baseline; “exchange list”; tolerance for flares
Carroll 2016, Hayden 2005
EXERCISE – GENERAL POINTS
• Discontinue cyclobenzaprine, in favor 
of nortriptyline 10 mg 
o Slow managed titration to 50 mg qhs
• Off opioids because previous 
prescriber no longer in local practice
o Consider periodic checking PDMP 
regardless
FOLLOW UP – 7/22/14 (2)





Millan 2002, Ossipov 2014
WHY NORTRIPTYLINE?
DESCENDING INHIBITORY CONTROL SYSTEMS  
L
C









*NNT = Number needed to treat
Saarto 2007
8/27/14
1. Nortriptyline + PT – reduction in widespread pain
2. Neck pain/headaches still present, but less
• Pain reduced 10%
• Rest of PEG improved 40%
• PHQ-4 = 4
3. Sleep better
4. Exam – reduced sensitivity of tender points
9/25/14
1. Nortriptyline – AM fatigue, some dry mouth
2. Pain still 6/10
3. Rest of PEG improved 60% from baseline
4. PHQ-4 = 2
FOLLOW UP, OVER MONTHS
• Cognitive:   
o Identify distressing negative cognitions and beliefs
• Behavioral approaches:  
o Mindfulness, relaxation, biofeedback
• Physical:  
o Activity coaching, graded exercise land & aquatic with PT, 
class, trainer, and/or solo
• Spiritual:  
o Identify and seek meaningfulness and purpose of one’s life
• Education (patient and family): 









• Most studies 
<3 months





See also: CDC 
Guideline for 
Prescribing Opioids for 
Chronic Pain—United 




PAIN TREATMENTS and EXTRAPOLATED 




























Cann is 10-30% 
CBT/Mindfulness 15-50%
Graded Exercise Therapy variable 
Sleep Restoration ≥ 40%
Hypnosis, Manipulation, Yoga “+ effect” 
11/5/14
1. Recent flare up of neck pain
2. Reviewed PT exercises – mainly stretching
3. Discuss neck/shoulder girdle strengthening
4. Sleep/fatigue – trazodone vs. more nortriptyline
2/10/15
1. Weight = 140 (BMI 22)
2. Sleep improved – nortriptyline, amitriptyline, 
trazodone
3. Worse UE sx’s; possible C6 radic – work up?
FOLLOW UP 
• Anticipate multiple symptoms
• Prepare for adversity
• Setting expectations is key
• Continuing re-evaluation
• Always consider psychosocial factors
Pain management takes time – many 
dimensions that evolve over time
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To Ask a Question
 Using the Webinar System
 “Click” the Q&A tab at the top left of the webinar tool bar
 “Click”  in the white space
 “Type” your question
 “Click” ask
 On the Phone
 Press Star (*) 1 to enter the queue
 State your name
 Listen for the operator to call your name 
 State your organization and then ask your question
Thank you for joining!
Centers for Disease Control and Prevention 
Atlanta, Georgia
http://emergency.cdc.gov/coca 
Today’s webinar  will be archived
When:  A few days after the live call
What:  All call recordings (audio, webinar, and 
transcript)
Where:  On the COCA Call webpage 
http://emergency.cdc.gov/coca/calls/2016/callinfo_072716.asp
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Continuing Education  for COCA Calls
All continuing education (CME, CNE, CEU, CECH, ACPE, CPH, and 
AAVSB/RACE) for COCA Calls are issued online through the CDC Training 
& Continuing Education Online system (http://www.cdc.gov/TCEOnline/).
Those who participated in today’s COCA Call and who wish to receive 
continuing education  should complete the online evaluation by August 
26, 2016 with the course code WC2286. Those who will participate in the 
on demand activity and wish to receive continuing education should 
complete the online evaluation between August 27 , 2016 and September 
26, 2018 will use course code WD2286. 
Continuing education certificates can be printed immediately upon 
completion of your online evaluation. A cumulative transcript of all 
CDC/ATSDR CE’s obtained through the CDC Training & Continuing 
Education Online System will be maintained for each user. 
Join the COCA 
Mailing List
Receive information about:
• Upcoming COCA Calls
• Health Alert Network notices
• CDC public health activations
• Emerging health threats
• Emergency preparedness and 








1 June 22 Guideline for Prescribing Opioids for 
Chronic Pain
2 July 27 Non-Opioid Treatments 
3 August 3 Assessing Benefits and Harms of 
Opioid Therapy 
4 August 17 Dosing and Titration of Opioids 
Join Us on 
Facebook
CDC Facebook page 
for clinicians! “Like” 
our page today to 
learn about upcoming 
COCA Calls, CDC 
guidance and 
recommendations, 
and other health alerts
CDC Clinician Outreach and Communication Activity
https://www.facebook.com/CDCClinicianOutreachAndCommunicationActivity
